We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.52B
AUM Growth
+$387M
Cap. Flow
+$63.5M
Cap. Flow %
2.52%
Top 10 Hldgs %
45.8%
Holding
129
New
32
Increased
30
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$33.4M
2
ABBV icon
AbbVie
ABBV
+$31.2M
3
AGN
Allergan plc
AGN
+$24M
4
BAX icon
Baxter International
BAX
+$22.3M
5
GILD icon
Gilead Sciences
GILD
+$20.2M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$59.8M
2
AGN
Allergan Inc
AGN
+$48.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.5M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$22.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.47%
2 Miscellaneous 11.07%
3 Real Estate 3.95%
4 Financials 1.4%
5 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BAX icon
26
Baxter International
BAX
$12.3B
$21.9M 0.87%
+588,384
New +$22.3M
PRGO icon
27
Perrigo
PRGO
$1.88B
$21.6M 0.86%
130,652
+67,700
+108% +$10.8M
VTR icon
28
Ventas
VTR
$45.4B
$21.4M 0.85%
256,389
– –
MDRX
29
DELISTED
Veradigm Inc. Common Stock
MDRX
$21.3M 0.84%
1,778,200
+173,600
+11% +$2.12M
JAZZ icon
30
Jazz Pharmaceuticals
JAZZ
$15.6B
$20.9M 0.83%
120,741
-80,600
-40% -$13.8M
RCPT
31
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$20.6M 0.82%
124,800
+104,400
+512% +$13.2M
NBIX icon
32
Neurocrine Biosciences
NBIX
$15.2B
$19.9M 0.79%
501,150
-499,200
-50% -$17.9M
IBB icon
33
iShares Biotechnology ETF
IBB
$10.3B
$19.8M 0.78%
173,010
– –
GEVA
34
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$19.4M 0.77%
198,689
-24,331
-11% -$2.58M
TMO icon
35
Thermo Fisher Scientific
TMO
$237B
$19M 0.75%
141,695
+20,700
+17% +$2.67M
DOC
36
DELISTED
PHYSICIANS REALTY TRUST
DOC
$18.5M 0.73%
1,050,902
+92,900
+10% +$1.57M
MPT
37
Medical Properties Trust
MPT
$2.11B
$17M 0.67%
1,153,574
+174,800
+18% +$2.6M
OHI icon
38
Omega Healthcare
OHI
$14.3B
$16.8M 0.66%
413,116
+36,700
+10% +$1.52M
IPXL
39
DELISTED
Impax Laboratories, Inc.
IPXL
$16.2M 0.64%
344,683
– –
MCK icon
40
McKesson
MCK
$105B
$15.3M 0.61%
67,862
– –
SBRA icon
41
Sabra Healthcare REIT
SBRA
$5.18B
$15.1M 0.6%
456,190
+48,300
+12% +$1.57M
KPTI icon
42
Karyopharm Therapeutics
KPTI
$34.9M
$14.6M 0.58%
31,798
+22,614
+246% +$9.75M
ALR
43
DELISTED
Alere Inc
ALR
$14.6M 0.58%
297,901
– –
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$31.9B
$13.6M 0.54%
130,195
+68,600
+111% +$6.95M
WELL.PRI
45
DELISTED
Welltower Inc.
WELL.PRI
$13.4M 0.53%
+200,000
New +$13.8M
ALXN
46
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$13.4M 0.53%
+77,200
New +$14M
HRTX icon
47
Heron Therapeutics
HRTX
$59.6M
$12.7M 0.5%
873,940
– –
VSTM icon
48
Verastem
VSTM
$665M
$12.7M 0.5%
104,152
+8,333
+9% +$874K
IRWD icon
49
Ironwood Pharmaceuticals
IRWD
$671M
$12.3M 0.49%
917,052
– –
ZBH icon
50
Zimmer Biomet
ZBH
$18.8B
$12M 0.48%
105,369
+23,175
+28% +$2.64M
1
2
3 4 5

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Tekla Capital Management held 129 positions worth $2.52B, up 18% from $2.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Tekla Capital Management's Q1 2015 filing shows 32 new, 30 increased, 16 reduced and 13 closed positions. Its largest new stake was Baxter International: 588,384 shares worth $21.9M. The largest sale was Shire pic, an estimated $59.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Real Estate.

  • Tekla Capital Management's largest Q1 2015 buy was Baxter International: 588,384 shares worth $21.9M.
  • Tekla Capital Management added most to Teva Pharmaceutical Industries Limited in Q1 2015, an estimated $33.4M increase.
  • Tekla Capital Management's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $28.5M.
  • Tekla Capital Management fully exited Shire pic in Q1 2015, selling an estimated $59.8M.
  • Tekla Capital Management's ten largest holdings make up 46% of its $2.52B portfolio in Q1 2015.
  • Tekla Capital Management opened 32 new positions and closed 13 in Q1 2015.
  • Tekla Capital Management's portfolio value rose 18% quarter-over-quarter to $2.52B.

Based on Tekla Capital Management's 13F filing for Q1 2015, filed 6 May 2015.